Thromb Haemost 1997; 77(02): 294-297
DOI: 10.1055/s-0038-1655956
Original Article
Schattauer GmbH Stuttgart

Qualitative Platelet 12-Lipoxygenase Abnormality in a Patient with Essential Thrombocythemia

Kenjiro Tomo
1   The First Division, Department of Internal Medicine, Tokushima University School of Medicine, Tokushima, Japan
,
Hiroshi Takayama
1   The First Division, Department of Internal Medicine, Tokushima University School of Medicine, Tokushima, Japan
,
Yoshiyuki Kaneko
2   Department of Clinical Molecular Biology, Faculty of Medicine, Kyoto University, Kyoto, Japan
,
Jun Fujita
2   Department of Clinical Molecular Biology, Faculty of Medicine, Kyoto University, Kyoto, Japan
,
Michihiro Nakamura
3   Department of Biochemistry, Tokushima University School of Medicine, Tokushima, Japan
,
Natsuo Ueda
3   Department of Biochemistry, Tokushima University School of Medicine, Tokushima, Japan
,
Shozo Yamamoto
3   Department of Biochemistry, Tokushima University School of Medicine, Tokushima, Japan
,
Minoru Okuma
1   The First Division, Department of Internal Medicine, Tokushima University School of Medicine, Tokushima, Japan
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Received 21. Dezember 1995

Accepted after revision 08. Oktober 1996

Publikationsdatum:
10. Juli 2018 (online)

Preview

Summary

Quantitative platelet 12-lipoxygenase (12-LOX) deficiency has been reported in some patients with myeloproliferative disorders (MPD). We report here for the first time a novel qualitative abnormality of the 12-LOX enzyme of platelets from a patient with essential thrombocythemia. The anti-12-LOX immunoprecipitates from the patient’s platelet homogenates showed a deficiency of 12-LOX activity, but contained normal amount of 12-LOX protein. There was no difference in subcellular localization of the enzyme between the patient’s platelets and normal ones. This 12-LOX protein lacking its enzyme activity showed slightly larger electrophoretic mobility than normal one, suggesting a molecular abnormality of the enzyme. However, we could not detect any genetic mutation causing such abnormalities in all exons of 12-LOX gene by sequencing the patient’s PCR-amplified DNA. Thus, our results indicate that the deficient activity of this abnormal 12-LOX protein is probably due to a posttranslational modification, and the possibility that platelets of some MPD patients have qualitative abnormality of the 12-LOX enzyme besides quantitative one.